Drug intelligence / Profile preview

CD19 CAR iNK cells

Development stage: Preclinical
Lead developer: Evotec
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CD19 CAR iNK cells are an off-the-shelf cellular therapy consisting of natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) and engineered to express a chimeric antigen receptor (CAR) targeting the CD19 antigen. Developed by Evotec, these cells are produced using a feeder-free 3D differentiation process from a validated GMP iPSC line. The therapy is designed to selectively eliminate CD19-positive B cells and plasma cells, which are implicated in the pathogenesis of various autoimmune disorders, such as systemic lupus erythematosus (SLE). By utilizing an iPSC-derived "iNK" platform, the product aims to provide a standardized, scalable alternative to autologous CAR-T cell therapies, potentially overcoming limitations related to cell dysfunction and manufacturing complexity in patients with autoimmune diseases.

Other names: iPSC-derived CD19 CAR NK cellsCD19 CAR-iNK cellsCD-19 CAR-iNK cellsCD 19 CAR-iNK cells

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CD19 CAR iNK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19 CAR iNK cells.

Explore the full profile